The pluripotency factor NANOG controls primitive hematopoiesis and directly regulates .

Progenitors of the first hematopoietic cells in the mouse arise in the early embryo from -positive multipotent cells in the posterior-proximal region of the epiblast, but the mechanisms that specify primitive blood cells are still largely unknown. Pluripotency factors maintain uncommitted cells of the blastocyst and embryonic stem cells in the pluripotent state. However, little is known about the role played by these factors during later development, despite being expressed in the postimplantation epiblast. Using a dual transgene system for controlled expression at postimplantation stages, we found that blocks primitive hematopoiesis in the gastrulating embryo, resulting in a loss of red blood cells and downregulation of erythropoietic genes. Accordingly, -deficient embryonic stem cells are prone to erythropoietic differentiation. Moreover, expression in adults prevents the maturation of erythroid cells. By analysis of previous data for NANOG binding during stem cell differentiation and CRISPR/Cas9 genome editing, we found that is a direct NANOG target. Our results show that regulates primitive hematopoiesis by directly repressing critical erythroid lineage specifiers.